Clinical trials
Second Line clinical trials
Below are recruiting second line clinical trials, each written for real people, not researchers. We’re tracking 122 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06839066RecruitingPhase 2
HLX43 for advanced nasopharyngeal cancer after prior treatments
This trial tests an investigational drug called HLX43 for people with nasopharyngeal cancer that has come back or spread, and who have already tried two or more prior treatments without success. The goal is to see if HLX43 can shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT06856187RecruitingPhase 2
Second-line chemo plus TAS-102 combo for advanced colorectal cancer
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
Shanghai, Shanghai MunicipalityAges Any age - NCT06876844RecruitingPhase 2
Surufatinib plus Envolizumab for advanced head and neck cancer
This study tests a new combination of two drugs (Surufatinib and Envolizumab) as a second treatment option for people with head and neck cancer that has returned or spread. It's for patients whose first treatment (usually chemo or immunotherapy) stopped working within 6 months.
ShanghaiAges 18–75 - NCT06929936RecruitingPhase 2
Trilaciclib plus docetaxel for advanced lung cancer (second-line+)
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
Xiamen, FujianAges 18 years+ - NCT07011576RecruitingPhase 2
Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
Denver, ColoradoAges 18 years+ - NCT07042919RecruitingPhase 1/Phase 2
Zanzalintinib for advanced liver cancer after prior treatment
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
Chicago, IllinoisAges 18 years+ - NCT07046611RecruitingPhase 2/Phase 3
Ketamine and Levetiracetam for Seizures in Children
This study tests whether two medicines, ketamine (a sleep medicine) and levetiracetam (a seizure medicine), work better than a standard treatment for stopping long-lasting seizures in children when the first rescue medicine doesn't work.
SohagAges 1–16 - NCT07047560RecruitingPhase 2
A new chemo combo for advanced colorectal cancer
This trial tests a different way of giving a chemotherapy drug called irinotecan, along with two other drugs (5-FU and bevacizumab), for people whose cancer got worse after first-line treatment. It aims to see if this combination can help control the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07073079Recruiting
Study of upadacitinib and risankizumab for Crohn's after first therapy
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
Castellana Grotte, BariAges 18 years+ - NCT07117981Recruiting
Study of second-line treatment for thyroid eye disease
This trial looks at how thyroid eye disease (inflammation behind the eyes) changes over time in people who need stronger treatments after steroids haven't worked well enough. It aims to better understand the disease and how different second-line treatments may help.
Paris, parisAges 18 years+ - NCT07188103RecruitingPhase 2
Ivonescimab and short radiation for advanced esophageal cancer
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
Hefei, AnhuiAges 18–80 - NCT07255378Recruiting
Vasopressin for septic shock in the ICU
This study observes how the medication vasopressin works when added to standard treatment for septic shock in the ICU. It helps doctors understand if vasopressin improves outcomes for patients with severe infection and low blood pressure.
Terrassa, BARCELONAAges 18 years+ - NCT01746836RecruitingPhase 2
Ponatinib for CML that didn’t respond to prior pills
This trial studies ponatinib as a second treatment for chronic myeloid leukemia (CML) when it didn’t fully respond or couldn’t be tolerated with at least one prior CML pill. It aims to see whether ponatinib can better control leukemia levels after earlier treatments.
Houston, TexasAges 18 years+ - NCT07466238Recruiting
Chemo into the liver plus IV chemo for bile duct cancer
This trial is testing a treatment plan that first delivers chemotherapy directly into the liver (through a thin tube) along with standard IV chemotherapy. The goal is to shrink the tumor enough to allow for surgery or less aggressive treatment later. It is for people with bile duct or gallbladder cancer that has not spread far.
BeijingAges 18–80 - NCT07469683RecruitingPhase 2
Combination therapy for advanced kidney cancer after first-line treatment
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
SeoulAges 19 years+ - NCT07559760RecruitingPhase 2
New combination therapy for advanced colorectal cancer after first treatment
This trial tests a new drug combination for colorectal cancer that has spread to other parts of the body and did not respond to or could not tolerate standard first-line chemotherapy. The goal is to see if this new approach can help shrink the cancer and extend survival.
Changchun, JilinAges 18–75 - NCT05479825Recruiting
Lung surgery planning without a tube, using X-ray guidance
This trial looks at a new way to plan a minimally invasive lung segment removal (“segmentectomy”) using live X-ray guidance, without using a chest tube (“tubeless”). It may help patients with certain small lung lesions (sometimes early lung cancer) get the surgery more precisely.
Jinan, Other (Non U.s.)Ages 18–85 - NCT05926700RecruitingPhase 2
Testing cadonilimab plus anlotinib for advanced soft tissue sarcoma
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
HangzhouAges 18 years+ - NCT07122024RecruitingPhase 4
Testing a dual therapy for H. pylori treatment
This trial tests a two-drug treatment (keverprazan and amoxicillin) for people who have H. pylori and have not been treated for it before. The goal is to see if this newer combination works well and is safe.
Hangzhou, ZhejiangAges 18–65 - NCT06482801RecruitingPhase 2
Immunotherapy combo for newly treated liver cancer
This trial tests a combination of immunotherapy drugs given directly into the liver’s blood supply as a first treatment for liver cancer. It aims to see if this approach can shrink tumors and improve outcomes for people with relatively preserved liver function.
GuangzhouAges 18–75 - NCT06554613RecruitingPhase 2
Olanzapine with first-line immunotherapy for advanced lung cancer trial
This trial tests whether adding the drug olanzapine to standard first-line immunotherapy (with or without chemotherapy) can help people with advanced lung cancer that does not have an EGFR mutation. It aims to improve treatment outcomes and quality of life.
Nanchang, JiangxiAges 18–75 - NCT07022223RecruitingPhase 2
Orelabrutinib plus rituximab for first treatment of marginal zone lymphoma
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
Hangzhou, ZhejiangAges 18 years+ - NCT06483347RecruitingPhase 2
Immunotherapy combo for inoperable lung cancer
This trial tests a combination of immunotherapy drugs (checkpoint inhibitors) delivered directly into the liver along with standard treatment, as a first option for people with inoperable lung cancer. It aims to see if this approach can help shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06951646RecruitingPhase 2
Personalized treatment for advanced lung cancer with long response to first-line therapy
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
ChangshaAges 18–75
Hear when a new Second Line trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for second line?
- Yes. Clin2 currently lists 122 recruiting second line studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a second line trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a second line trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.